Kodiak Sciences Inc. , today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bwcc18604 ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...

Physicians’ Education Resource (PER®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting ...

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...